New York, USA – October 9, 2020 – Acroscell, the division of Creative Bioarray specialized in offering high-quality products and services in order to promote the development of cardiac & neuronal safety profiling and translational assays for the academia, pharmaceutical, and biotechnology industries. Recently Acroscell announces the releases of its professional technique named Multi-Electrode Array in order to analyze complex drug effects on ion channel interactions and cell signaling in cellular networks including stem-cell derived approaches, tissue slices and isolated organs.
Microelectrode array (MEA) is one of the most advanced and effective techniques for measuring changes in spontaneously active cells (such as cardiomyocytes and neurons). With decades of expertise in MEA testing and production, Acroscell has become an expert in the development and application of MEA-based drug screening methods.
In the cardiac safety analysis, Acroscell’s MEA test can be used to test the function of ventricular cardiomyocytes derived from human induced pluripotent stem cells. iPSC-derived cardiomyocytes are suitable for electrophysiology-based microelectrode array (MEA) analysis related to predictive preclinical safety pharmacology, toxicology and efficacy testing.
The combination of iPSC-derived cardiomyocytes and the MEA system can perform detailed electrophysiology on the potential cardiotoxicity/pro-arrhythmic effects of compounds (such as ion channel blockers) under non-invasive, label-free fluxes of up to 96 wells Detection. As a high-throughput functional platform, MEA can be used to detect prolongation, changes in beat frequency, and arrhythmia events.
Acroscell provides a central phenotype analysis platform, including manual patch clamp and multi-electrode array (MEA) technology to establish compound target verification, target participation and species selectivity. Alternatively, these methods can be used to perform electrophysiological characterization of cells with different etiologies. Monitor physiological activity from natural tissues (such as rodent cortical neurons) or other cell types (such as cells derived from stem cells).
In Acroscell, all compounds can be evaluated in vitro under the most physiologically relevant conditions. All receptors, channels, and enzymes are natural and have all the functions of signal transduction and regulation pathways. While MEA applied in neuroscience research, slices can be prepared from many different brain regions, and all neurons and glial cells are placed in appropriate positions and connected to each other as if they were in the body.
“In addition to classic electrophysiological methods, Acroscell also provides an in vitro test system based on microelectrode array (MEA) recording to analyze the effects of complex drugs on ion channel interactions and cell signaling in cell networks, including stem cell-derived methods, tissues Sectioned and isolated organs,” said Hannah Cole, the marketing director of Creative Bioarray, she also claimed, “Acroscell is always dedicated to satisfy the requirements of our clients, we are also capable to bring out customized solutions for specific needs.”
As a mature division of Creative Bioarray, Acroscell definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.